## Th2 Cytokine Axis in Atopic Dermatitis **Key Point:** Atopic dermatitis is fundamentally a Th2-mediated immune disorder characterized by elevated IL-4 and IL-13, which are now the primary therapeutic targets in moderate-to-severe AD. ### IL-4 and IL-13 Signaling Both cytokines signal through the IL-4 receptor alpha (IL-4Rα) subunit: - IL-4 binds to IL-4Rα + γc (Type I receptor) - IL-13 binds to IL-4Rα + IL-13Rα1 (Type II receptor) - Both pathways converge on STAT6 phosphorylation ### Downstream Effects of IL-4/IL-13 1. **IgE production** — B cell class switching to IgE 2. **Th2 differentiation** — amplification of Th2 response 3. **Barrier dysfunction** — reduced filaggrin and tight junction proteins 4. **Eosinophil recruitment** — via eotaxin production 5. **Pruritus** — via TRPV1 sensitization **High-Yield:** Dupilumab is a monoclonal antibody against IL-4Rα that blocks both IL-4 and IL-13 signaling simultaneously, making it highly effective in AD. ### Dupilumab Efficacy - FDA-approved for moderate-to-severe atopic dermatitis - Rapid onset of action (improvement within 2–4 weeks) - Improves pruritus, skin barrier function, and systemic inflammation - Also approved for asthma and chronic rhinosinusitis with nasal polyps (Th2-mediated conditions) **Mnemonic:** **STAT6** — the transcription factor activated by IL-4Rα signaling drives Th2 differentiation and IgE production. **Clinical Pearl:** The Th2-dominant phenotype in AD explains the frequent association with allergic rhinitis, asthma, and food allergy — the "atopic triad." 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.